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Abstract: Despite high-level evidence, the benefit of postmastectomy
RT in these patients in recent years has not been fully elucidated. We
investigated postmastectomy radiotherapy (RT) use and evaluated
clinicopathologic and treatment factors influencing RT use in Korean
women with pT1-2N1 breast cancer.
We identified women diagnosed with pT1-2N1 breast cancer
between 1994 and 2009 using the Korean Breast Cancer Registry.
Factors associated with RT use were evaluated using logistic regression
analysis. The median follow-up was 95 months.
Of the 6196 women, 11.9% underwent postmastectomy RT. RT was
applied more frequently in women with 3 positive lymph nodes
(adjusted odds ratio [OR], 2.69) and larger tumors (OR per centimeter,
1.10). RT use was not significantly associated with well-established risk
factors (e.g., tumor grade, hormone receptor status, and lymphovascular
space invasion). Although RT utilization increased gradually during the
study period (OR per year, 1.07), factors associated with RT were
similar over time. The estimated 5-year overall survival increased
significantly from 84.1% in 1994 to 2000 to 94.6% in 2005 to 2009.
This population-based analysis revealed that the indications for
postmastectomy RT in pT1-2N1 breast cancer in Korea are based solely
on conventional anatomical factors, although their survival hashemodern treatment era. There is a significant
stratification in these patients and for tailored
n of tumor biology-associated factors.
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Abbreviations: AC = doxorubicin and cyclophosphamide,
ACOSOG = American College of Surgeons Oncology Group,
DSS = disease-specific survival, ECOG = Eastern Cooperative
Oncology Group, EORTC = European Organization for Research
and Treatment of Cancer, KBCR = Korean Breast Cancer Registry,
LRR = locoregional recurrence, LVI = lymphovascular space
invasion, NCIC-CTG = National Cancer Institute of Canada
Clinical Trials Group, NSABP = National Surgical Adjuvant
Breast and Bowel Project, OS = overall survival, PET = positron-
emission tomography, pN1mi = micrometastases, RT =
radiotherapy, SLNB = sentinel lymph node biopsy, T-based =
paclitaxel-containing regimens.
INTRODUCTION
I n patients with breast cancer, nodal status is a significantfactor for the prognostication and selection of adjuvant radio-
therapy (RT).1 Randomized trials have demonstrated survival
benefits for patients with node-positive breast cancer who
underwent mastectomy and adjuvant RT, compared with those
who underwent mastectomy alone.2–4 Despite high-level evi-
dence, the use of postmastectomy RT is still controversial in
women with the involvement of 1 to 3 axillary lymph nodes
(pN1). With contemporary multidisciplinary management,
overall survival (OS) has been increasing in patients treated
since 2000 compared with that in those treated in earlier trials,5–
7 and the locoregional recurrence (LRR) risk is likely to be
correspondingly lower in these patients.5–7 In this respect, the
present absolute benefits of postmastectomy RT for pT1-2N1
breast cancer are likely to be small.
Given the excellent recent treatment outcomes, there is no
consensus on the definite indication for postmastectomy RT in
patients with pN1 breast cancer. A number of risk factors for
LRR following mastectomy alone, including large tumor
size, unfavorable tumor biology, or young age, have been
reported.7–9 This knowledge can guide careful patient selection
for postmastectomy RT to avoid unnecessary local therapy
because RT may have detrimental impacts in terms of breast
cosmetics, late toxicity, and associated costs.10 A better under-
standing of RT use is important to optimize patient care.
We hypothesized that because OS has increased, patients
may have been selected more appropriately for postmastectomy
RT in Korea. Therefore, the objective of this study was to
determine the survival in patients with pT1-2N1 breast cancer
and describe the trend of RT use in Korea using the Korean
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Breast Cancer Registry nationwide database. In addition, we
evaluated the impact of clinicopathologic and treatment factors
on RT use.
METHODS
Data Source and Collection
The Korean Breast Cancer Society has assembled infor-
mation on breast cancer since 1996. The details of the Korean
Breast Cancer Registry (KBCR) have been described pre-
viously.11–13 In brief, nationwide, breast surgeons in 110 teach-
ing hospitals have voluntarily participated in the KBCR
program. These surgeons prospectively collect data on sex,
age, surgical method used, and cancer stage as essential items,
and operative and pathologic findings, laboratory and imaging
findings, biologic markers, and adjuvant treatment as optional
items. This registry comprised about 92.0% of all newly diag-
nosed breast cancer patients in Korea in 2011. Survival data,
including dates and causes of death, were obtained from the
Korean Central Cancer Registry, Ministry of Health and Wel-
fare, Korea. The KBCR is linked to the Korean National
Statistical Office with complete death statistics using unique
identification numbers assigned to all Korean residents, and was
recently updated in 2013. The KBCR does not include infor-
mation regarding tumor recurrence.
Chang et alescription of the Study Cohort
Patients were eligible for analysis if they were diagnosed
ith invasive ductal carcinoma of the breast and underwent
tectomy to death from breast cancer, women who died of othe
causes were censored at the time of death). Univariate and
multivariate Cox proportional hazards survival analyses wereD
wFIGURE 1. Selection of the study cohort. PMRT¼postmastectomy ra
2 | www.md-journal.commastectomy between January 1, 1994 and December 31, 2009.
Exclusion criteria are shown in Figure 1. We excluded patients
without information on the receipt of postmastectomy RT. The
final study cohort comprised 6196 women with complete data.
The median follow-up period was 95 months (range, 37–229
months) and 5-year follow-up data were available in 84% of
patients. The review board of the Korean Breast Cancer Society
approved this study. The institutional review board of Severance
Hospital concluded that no informed consents were needed for
this observational and retrospective study.
Statistical Analyses
The proportion of women who underwent postmastectomy
RT over specific periods was the primary endpoint. Univariate
and multivariate logistic regression analyses were conducted to
assess whether there was an association between the year of
mastectomy, age, tumor size, number of lymph nodes involved,
tumor grade, hormone-receptor status, lymphovascular space
invasion (LVI), method of axillary clearance, number of
retrieved nodes, use of adjuvant chemotherapy, breast recon-
structive surgery, and receipt of postmastectomy RT. To further
investigate whether patterns changed over time, the year of
mastectomy was categorized into 3 periods (1994–2000, 2001–
2004, and 2005–2009), and the same analyses were conducted.
Secondary endpoints included OS (from mastectomy to any
cause of death) and disease-specific survival (DSS, from mas-
Medicine  Volume 95, Number 19, May 2016diation therapy.
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TABLE 1. Clinicopathologic and Treatment Characteristics,
pT1-2N1 Breast Cancer, 1994–2009, Korean Breast Cancer
Society
Characteristics No. of Patients %
Age, y
<40 1129 18.1
40–49 2394 38.8
50–64 2023 32.7
65 640 10.4
Tumor size, cm
<1 395 6.4
1–1.9 1385 22.4
2–2.9 2216 35.8
3–3.9 1317 21.3
4–5 756 12.2
Unknown 127 2.0
Number of involved lymph node
1 3189 51.5
2 1808 29.2
3 1199 19.4
Grade
I 631 10.2
II 2790 45.0
III 2132 34.3
Unknown 643 10.4
ER status
Negative 2179 35.2
Positive 3778 61.0
Unknown 239 3.9
PR status
Negative 2585 41.7
Positive 3375 54.5
Unknown 236 3.8
LVI
Absent 2322 37.5
Present 2254 36.4
Unknown 1620 26.1
Axillary clearance
ALND 4356 70.3
SLNB þ ALND 1840 29.7
Number of removed lymph node
Median 16
Range 1–69
Mean (SD) 16.8 (7.8)
Adjuvant chemotherapy
No 419 6.8
Yes 5763 93.0
Unknown 14 0.2
Adjuvant endocrine therapy
No 1785 28.8
Yes 4111 66.3
Unknown 300 4.8
Adjuvant radiation therapy
No 5459 88.1
Yes 737 11.9
Breast reconstructive surgery
No 5665 91.4
Yes 531 8.6
Vital status
Dead 907 14.6
Alive 5289 85.4
Use of PMRT in T1/2N1 Breast Cancerperformed to model the association of variables with OS or
DSS. Conditional landmark analysis was used to eliminate
guarantee-time bias introduced by misclassification of patients
without adjuvant treatments who had died before reaching last
follow-up.14 The level of statistical significance was set at 5%.
All statistical analyses were performed using SPSS version 20.0
(IBM SPSS Statistics, IBM Corporation, Armonk, NY).
RESULTS
Patient Clinicopathologic and Treatment
Characteristics
The baseline clinicopathologic and treatment character-
istics of this study cohort are described in Table 1. The median
patient age at diagnosis was 48 years (range, 24–94 years).
Among patients with available pathology (n¼ 4576), 49.3% of
patients had LVI. No patients underwent sentinel lymph node
biopsy (SLNB) alone for pT1-2N1 after mastectomy within the
study period. Among patients who underwent chemotherapy
(n¼ 5763), 35.8%, 23.5%, and 33.6% of patients received
paclitaxel-containing regimens (T-based), doxorubicin and
cyclophosphamide (AC), and others (e.g., cyclophosphamide/
methotrexate/fluorouracil), respectively.
Factors Associated With Postmastectomy RT
Factors associated with having undergone postmastectomy
RTwere as follows: age<40 years (vs. age 50–64 years; adjusted
odds ratio [aOR], 1.95; 95% confidence interval [CI], 1.50–2.53;
P<0.001); age 40–49 (vs. age 50–64 years; aOR, 1.25; 95% CI,
1.00–1.56; P¼ 0.054); larger tumor size (per centimeter; aOR,
1.11; 95%CI, 1.01–1.21;P¼ 0.025); and 3 positive lymphnodes
(aOR, 2.71; 95% CI, 2.20–3.33; P<0.001). Factors inversely
associated with having undergone postmastectomy RT were as
follows: age65 years (vs. age 50–64 years; aOR, 0.55; 95%CI,
0.35–0.85; P¼ 0.007); a greater number of retrieved lymph
nodes (aOR, 0.98; 95% CI, 0.96–0.99; P<0.001); and breast
reconstructive surgery (aOR, 0.44; 95% CI, 0.30–0.65;
P<0.001) (Table 2). Multivariate analyses revealed a significant
independent association between the proportion of patients
undergoing postmastectomy RT and time (increasing each year)
(aOR, 1.05; 95% CI, 1.02–1.09; P¼ 0.003).
Subgroup Analysis of RT Use by Treatment
Period
In the subgroup analysis, the postmastectomy RT utiliz-
ation rate significantly increased as the treatment period
advanced, with higher proportions of patients undergoing RT
in the modern treatment period eras (X2 trend test, P<0.001,
Table 3). The differences between RT use trends and patterns in
adverse features during 1994 to 1999, 2000 to 2004 vs 2005 to
2009 are listed in Table 3. Age and the number of positive
lymph nodes correlated with RT receipt regardless of the period,
as would be expected. However, unexpectedly, the proportion
of patients with small tumors (<2 cm) who underwent post-
mastectomy RT significantly increased between 1994 and 2000
and between 2005 and 2009 (5.8% vs. 13.8%, respectively).
Postmastectomy RT use was not likely to be affected by tumor
grade, hormone receptor status, or LVI across any study period.
Medicine  Volume 95, Number 19, May 2016Survival Analyses
Figure 2 and Table 4 shows the estimated survival among
all patients according to period. The estimated 5-year OS and
ALND¼ axillary lymph node dissection, ER¼ estrogen receptor,
LVI¼ lymphovascular invasion, PR¼ progesterone receptor,
SD¼ standard deviation, SLNB¼ sentinel lymph node biopsy.
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whether the chemotherapy regimen affected the survival out-
TABLE 2. Unadjusted and Adjusted Odds Ratios for Association With Receipt of Adjuvant Radiation Therapy for pT1-2N1 Breast
Cancer for Each Clinicopathologic and Treatment Characteristic

RT (%)
Univariable Multivariable
Covariate No. of Patients Receipt Odds Ratio 95% CI P Odds Ratio 95% CI P
Year of mastectomy
(per year)
6196 1.08 1.05–1.10 <0.001 1.05 1.02–1.09 0.003
Age, y
<40 1121 15.3 1.59 1.28–1.97 <0.001 1.95 1.50–2.53 <0.001
40–49 2394 12.6 1.27 1.06–1.54 0.012 1.25 1.00–1.56 0.054
50–64 2023 10.2 1 [Reference] — 1 [Reference] —
65 640 6.4 0.60 0.43–0.86 0.004 0.55 0.35–0.85 0.007
Tumor size (per
centimeter)y
6196 1.09 1.01–1.18 0.021 1.11 1.01–1.21 0.025
Number of involved LN
1–2 4997 9.7 1 [Reference] — 1 [Reference] —
3 1199 21.0 2.48 2.09–2.93 <0.001 2.71 2.20–3.33 <0.001
Gradey — —
I 631 12.8 1 [Reference] 1 [Reference] —
II 2790 11.6 0.89 0.69–1.15 0.376 0.82 0.61–1.10 0.179
III 2132 11.4 0.87 0.66–1.14 0.308 0.80 0.58–1.10 0.172
ER/PR statusy
Positive 4181 11.6 1 [Reference] — 1 [Reference] —
Negative 1784 12.6 1.09 0.92–1.30 0.296 1.05 0.84–1.31 0.658
LVIy
Absent 2322 13.0 1 [Reference] — 1 [Reference] —
Present 2254 13.5 1.04 0.88–1.24 0.631 0.95 0.79–1.15 0.591
Axillary clearance — —
ALND 4356 11.0 1 [Reference] — 1 [Reference] —
SLNB þ ALND 1840 14.0 1.31 1.11–1.54 0.001 1.24 1.02–1.51 0.035
Number of removed
LN (per no.)y
6196 0.98 0.97–0.99 0.001 0.98 0.96–0.99 <0.001
Adjuvant chemotherapyy — —
No 419 5.3 1 [Reference] — 1 [Reference] —
Yes 5763 12.4 2.55 1.65–3.94 <0.001 1.55 0.87–2.78 0.140
Breast reconstructive
surgeryy
— —
No 5665 12.3 1 [Reference] — 1 [Reference] —
Yes 531 7.2 0.55 0.39–0.77 0.001 0.44 0.30–0.65 <0.001
ALND¼ axillary lymph node dissection, CI¼ confidence interval, ER¼ estrogen receptor, LN¼ lymph node, LVI¼ lymphovascular invasion,
PR¼ progesterone receptor, RT¼ radiation therapy, SLNB¼ sentinel lymph node biopsy.
Odds ratios based on logistic regression modeling. Model covariates included year of surgery, age, tumor size, nodal status, grade, ER/PR status,
LVI, receipt of SLNB, number of LN retrieved, receipt of adjuvant chemotherapy, and receipt of breast reconstructive surgery.
y
Chang et al Medicine  Volume 95, Number 19, May 2016DSS significantly increased from 84.1% and 85.4% for 1994 to
2000 to 94.6% and 95.6% for 2005 to 2009, respectively
(adjusted hazard ratio per year, 0.86; 95% CI, 0.83–0.88).
Table 5 presents the multivariate Cox proportional hazards
survival analyses at the 16-month landmark point including all
variables listed in Table 1. Postmastectomy RT was not associ-
ated with any differences in mortality rates. Factors associated
with superior OS included later year of mastectomy, age (<50
years), SLNB followed by axillary lymph node dissection,
breast reconstructive surgery, and greater numbers of retrieved
lymph nodes. Factors associated with inferior OS included age
P values were calculated after unknown values were excluded.(65 years), larger tumor size, higher grade tumor, negative
hormone receptor status, and positive LVI. Findings were
similar for DSS. Table 6 shows an additional subset analysis
4 | www.md-journal.comfor patients who received adjuvant chemotherapy to determinecome. AC or T-based regimens were significantly associated
with superior OS and DSS compared with other regimens.
DISCUSSION
The present study highlights national practice patterns in
RT utilization following mastectomy in patients with pT1-2N1
breast cancer in Korea, and the factors associated with RT use,
which can both be useful in guiding current clinical practice in
the right direction. Surprisingly, we found that only 11.9% of
patients received RT after mastectomy, but that the numbers of
patients receiving RT increased gradually per year from 1994 to
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Use of Adjuvant Radiation Therapy for pT1-2N1 Breast Cancer in Adverse Features During 1994–2000 Versus
2001–2004 Versus 2005–2009
1994–2000 (n¼ 775) 2001–2004 (n¼ 2336) 2005–2009 (n¼ 3085)
N % N % N %
Overall rateofRTuse%whoreceivedRT 57/775 7.4 244/2336 10.4 436/3085 14.1
Age, y
<40 24/193 12.4 51/429 11.9 96/499 19.2
40–49 21/308 6.8 122/923 13.2 159/1163 13.7
50–64 9/219 4.1 58/746 7.8 139/1058 13.1
65 3/55 5.5 11/235 4.7 27/350 7.7
Tumor size, cm
<1 2/32 6.3 14/117 12.0 45/246 18.3
1–1.9 9/158 5.7 37/435 8.5 98/792 12.4
2–2.9 19/277 6.9 79/882 9.0 122/1057 11.5
3–3.9 11/170 6.5 67/566 11.8 85/581 14.6
4–5 14/111 12.6 31/282 11.0 68/363 18.7
Lymph node involvement
1–2 34/624 5.4 158/1852 8.5 293/2521 11.6
3 23/151 15.2 86/484 17.8 143/564 25.4
Grade
I 5/66 7.6 24/214 11.2 52/351 14.8
II 20/324 6.2 113/1045 10.8 190/1421 13.4
III 7/201 3.5 81/792 10.2 154/1139 13.5
ER/PR status
Positive 12/196 6.1 81/718 11.3 131/870 15.1
Negative 30/448 6.7 152/1535 9.9 303/2198 13.8
LVI
Absent 13/117 11.1 86/680 12.6 204/1525 13.4
Present 19/89 21.3 90/869 10.4 196/1296 15.1
ster
Medicine  Volume 95, Number 19, May 2016 Use of PMRT in T1/2N1 Breast Cancer2009. During this period, women with larger tumors and more
positive lymph nodes were likely to receive RT, but we did not
observe significant differences in relation to other well-estab-
lished risk factors including LVI, high-grade tumor, and estro-
gen receptor-negative status. For women treated in the 2000s,
ER¼ estrogen receptor, LVI¼ lymphovascular invasion, PR¼ progewho had a significantly better OS and DSS than those treated in
the 1990s, this concerning trend of patient selection for RT may
be against ‘‘choosing wisely.’’
FIGURE 2. Survival outcomes for patients with pT1-2N1 breast cancer.
survival. HR¼hazard ratio.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.A number of possibilities could underlie the improvements in
the survival outcome over time. Prior to 2010, the KBCR database
did not record pathologic information on small volume axillary
disease.However, givenour findings thatSLNBwas independently
associated with a higher OS and that the number of patients
one receptor, RT¼ radiation therapy.undergoing SLNB increased over time, an increase in the detection
of small volume nodal metastasis, including micrometastases
(pN1mi), by extensive pathologic evaluation following SLNB
Kaplan–Meier curves for (A) overall survival and (B) disease-specific
www.md-journal.com | 5
TABLE 4. Five-Year Overall and Disease-Specific Survivals for
Patients With pT1-2N1 Breast Cancer According to Time
Period, 1994–2009, Korean Breast Cancer Society
Time Period 5-Y OS

95% CI 5-Y DSSy 95% CI
94–99 84.1% 81.6–86.6% 85.4% 82.9–87.9%
00–04 87.8% 86.4–89.2% 94.1% 93.1–95.1%
05–09 94.6% 93.8–95.4% 95.6% 94.8–96.4%
CI¼ confidence interval, DSS¼ disease-specific survival,
OS¼ overall survival.
Overall survival (Group 05–09 vs. 94–99, Bonferroni corrected P
values [Pc] <0.001, Group 05–09 vs. 00–04, Pc <0.001, Group 00–04
vs. 94–99, Pc <0.001).y
Chang et alcould be the most plausible reason for improved survival. In an
analysis of>8000 patients from 2 large cohorts, Mittendorf et al15
reported that patients with pN1mi and pN0 disease have similar
survival outcomes. Parallel findings were reported in 2 other recent
analyses from the American College of Surgeons Oncology Group
(ACOSOG) Z0010 and the National Surgical Adjuvant Breast and
Bowel Project (NSABP)B32 trials.16,17AnongoingRxPonder trial
evaluating the utility ofOncotypeDx in patientswith 1 to 3 positive
lymph nodes and hormone receptor-positive tumors recently
amended the protocol to exclude patients with pN1mi. Taken
together, we feel that the benefit of RT would be diminished in
these patients and that postmastectomy RT should not be deter-
mined primarily by the presence of pN1mi disease.18
Our findings showed that patients treated in later years
were more likely to undergo a modern chemotherapy (ACT)
regimen, and that modern chemotherapy was significantly
associated with improved OS. This suggests that advances in
adjuvant systemic treatments might also contribute to improved
survival outcomes.19 With growing evidence supporting mod-
ern chemotherapy and targeted agents, it seems essential to
determine the relative contribution of each component of
adjuvant treatment.20 Earlier trials that showed the 10-year
LRR rate in those who did not undergo RT was 17.7%, although
most of those patients also underwent a CMF chemotherapy
regimen.5 On the other hand, trials from the NSABP and the
Eastern Cooperative Oncology Group reported a 10-year LRR
rate of <10% in those who did not undergo RT, and most of
them received modern chemotherapy.6,7 This further supports
the hypothesis that there is less room for improvement by RT in
those undergoing modern chemotherapy.
These findings raise the question of whether RT could be
omitted in T1-2N1 patients who undergo modern systemic
therapy postmastectomy, especially in the era of SLNB and
in those expected to have a very low risk for LRR. However,
there are data emphasizing the importance of RT in these
patients. A recent study by Chang et al18 showed a significant
improvement in disease-free survival by postmastectomy RT in
recently treated patients who were at extremely low risk of
LRR, indicating recent treatment advances might not mitigate
the benefit of RT in these N1 subsets of patients. Interestingly,
recent data from both the National Cancer Institute of Canada
Clinical Trials Group (NCIC-CTG) MA.20 and the European
Disease-specific survival (Group 05–09 vs. 94–99, Pc <0.001,
Group 05–09 vs. 00–04, Pc <0.001, Group 00–04 vs. 94–99, Pc
<0.001).Organization for Research and Treatment of Cancer 22922 trials
indicated that the addition of comprehensive regional nodal
irradiation in the treatment of breast-conserved patients
6 | www.md-journal.comprovided a small but statistically significant benefit in dis-
ease-free survival.21,22 N1 patients constituted 90% of the
NCIC-CTG MA.20 cohort and 43% of the European Organiz-
ation for Research and Treatment of Cancer 22922 cohort.
While data from the SUPREMO trial are awaited, which
specifically investigates whether postmastectomy RT improves
survival in patients with an intermediate risk of local recurrence,
including N1 patients, physicians should pay careful attention to
the selection of candidates for postmastectomy RT.23
In this study, we found that RT was underutilized in Korean
patients with pT1-2N1 breast cancer patients, and that its use was
considerably lower than that in North American patients (11.9%
vs. 19–25%, respectively).24,25 This stands in contrast to current
international guidelines, including NCCN in recent years inclus-
ive of 2016, even after allowing for improved survivals of these
subsets of patients recently.26Our findingswith respect to gradual
increases in RT use also suggest conservative responsiveness of
the breast cancer community to emerging evidence. While 1
overriding cause is difficult to determine, substantial underuti-
lizationofRT inN1mastectomypatients can largely be explained
by the results of a study by Jagsi et al.27 That large, population-
based study found high rates of RT use in breast conserved
patients, but lower rates among mastectomy patients. For most
mastectomy patients with strong indications for RT who failed to
undergo PMRT, patient self-report indicated that physicians
either did not discussRTor said that itwasunnecessary.Concerns
about the adverse effects, inconveniences, and associated costs of
RT may also contribute to underutilization of adjuvant postmas-
tectomy RT in Korean patients. However, the potential for
toxicity from breast RT has decreased with the introduction of
more advanced RT technologies including RT planning with
computed tomography-based RT simulation and three-dimen-
sional conformal RT delivery. Especially, CT-based RT simu-
lation planning assists radiation oncologists in delineating the
organs at risk more precisely, in estimating the complication
probabilities, and in minimizing the irradiated volume. Intensity-
modulated radiation therapy, which has the advantage of improv-
ing dose homogeneity and sparing normal tissue, was covered by
the Korean National Health Insurance for postmastectomy RT in
breast cancer in July 2015, which may alleviate concerns regard-
ing toxicity to some degree.28 Although large randomized trials
that established the role of hypofractionated RT in breast cancer
excluded postmastectomypatients, there are retrospective studies
supporting the use of hypofractionated RT in these patients,
which compliment an ongoing phase III randomized trial
(NCT00793962).29 With respect to patients’ convenience, hypo-
fractionated RT might be possible treatment approach to reduce
both cost and burden.
In a time of growing concern about local therapy under or
over treatment, continued efforts are needed to investigate
clinical, metabolic, and molecular markers for better risk stra-
tification and appropriate patient selection. In our study, the
number of positive lymph nodes, number of lymph nodes
resected, tumor size, and age were found to be predictive
clinical factors associated with RT use, which was similar to
the findings of a systematic review of the NSABP trials.7 The
lymph node ratio, which combined number of positive lymph
nodes with the number of lymph nodes removed, could identify
patients who might benefit most from RT.30,31 In our study, RT
use was more common among younger than older women,
reflecting the concern that younger age is in itself a risk factor
Medicine  Volume 95, Number 19, May 2016for local recurrence following mastectomy.32 However,
peculiarly enough, young age has not clearly been shown to
be a predictor of survival from our cohort that included only
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 5. Multivariable Cox Proportional Hazards Analyses of Overall Survival and Disease-Specific Survival at the 16-Month
Landmark Point, pT1-2N1 Breast Cancer, 1994–2009, Korean Breast Cancer Society
OS Analysis DSS Analysis
Covariate No. of Patients HR 95% CI P HR 95% CI P
Year of mastectomy
(per year)
6118 0.84 0.81 — 0.87 <0.001 0.86 0.82 — 0.89 <0.001
Age, y
<40 1107 0.62 0.44 — 0.86 0.004 0.41 0.26 — 0.65 <0.001
40–49 2374 0.81 0.63 — 1.03 0.080 0.75 0.56 — 1.00 0.050
50–64 1995 1 [Reference] — 1 [Reference] —
65 625 1.63 1.21 — 2.21 0.001 1.39 0.95 — 2.03 0.085
Tumor size
(per centimeter)
6118 1.19 1.07 — 1.31 0.001 1.32 1.17 — 1.49 <0.001
Number of involved LN
1–2 4941 1 [Reference] — 1 [Reference] —
3 1177 1.03 0.80 — 1.33 0.807 0.94 0.69 — 1.29 0.717
Grade
I 629 1 [Reference] — 1 [Reference] —
II 2765 1.66 1.08 — 2.55 0.021 2.08 1.14 — 3.77 0.016
III 2094 2.03 1.30 — 3.16 0.002 2.51 1.36 — 4.63 0.003
ER/PR status
Positive 4151 1 [Reference] — 1 [Reference] —
Negative 1744 1.83 1.35 — 2.47 <0.001 1.56 1.07 — 2.28 0.020
LVI
Absent 2307 1 [Reference] — 1 [Reference] —
Present 2220 1.51 1.23 — 1.85 <0.001 1.63 1.27 — 2.11 <0.001
Axillary clearance
ALND 4289 1 [Reference] — 1 [Reference] —
SLNB þ ALND 1829 0.66 0.51 — 0.86 0.002 0.74 0.54 — 1.00 0.051
Number of removed
LN (per no.)
6118 0.98 0.97 — 0.99 0.002 0.97 0.95 — 0.99 <0.001
Adjuvant chemotherapy
No 392 1 [Reference] — 1 [Reference] —
Yes 5712 0.71 0.47 — 1.05 0.089 0.93 0.54 — 1.62 0.809
Adjuvant endocrine therapy
No 1745 1 [Reference] — 1 [Reference] —
Yes 4076 0.95 0.71 — 1.28 0.752 0.79 0.54 — 1.14 0.199
Breast reconstructive surgery
Yes 527 1 [Reference] — 1 [Reference] —
No 5591 0.31 0.14 — 0.65 0.002 0.19 0.06 — 0.61 0.005
Adjuvant radiation therapy
No 5391 1 [Reference] — 1 [Reference] —
Yes 727 1.16 0.85 — 1.57 0.345 1.24 0.86 — 1.78 0.246
ALND¼ axillary lymph node dissection, CI¼ confidence interval, DSS¼ disease-specific survival, ER¼ estrogen receptor, HR¼ hazard ratio,
LN¼ lymph node, LVI¼ lymphovascular invasion, NA¼ not applicable, OS¼ overall survival, PR¼ progesterone receptor, SLNB¼ sentinel lymph
node biopsy.
Medicine  Volume 95, Number 19, May 2016 Use of PMRT in T1/2N1 Breast Cancerearly stage women. Given the fact that younger women usually
present with larger tumors and higher percentage of positive
lymph nodes, much care is needed to consider age in post-
mastectomy RT decision making in women with early-stage
disease.33 Recently, many investigators have identified other
risk factors for LRR in institutional cohorts who did not undergo
RT, such as high-grade tumor, estrogen receptor negativity,
and LVI.34–36 The present study also found that these well-
established risk factors were associated with poor survival
outcome, but that they did not affect RT utilization. Previous
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.study have shown that biologic factors including tumor grade
and estrogen receptor status could be used as prognostic mar-
kers and even more so in those with small-volume nodal
disease.15 These results indicate that estrogen receptor status,
tumor grade, and LVI should be considered alongside T and N
stage in multidisciplinary discussions to decide whether to
implement RT.Recent studies reported the utility of pretreatment posi-
tron-emission tomography (PET) for predicting high-risk
patients who could be candidates for RT among patients with
www.md-journal.com | 7
TABLE 6. Univariable Cox Proportional Hazards Survival Analysis According to Chemotherapy Regimen Among pT1-2N1 Breast
Cancer Patients Who Received Chemotherapy and Had Available Data on Regimen, 2000–2009, Korean Breast Cancer Society
OS Analysis DSS Analysis
Covariate No. of Patients 5-Y (%) HR 95% CI P 5-Y (%) HR 95% CI P
Regimen —
T-based 2219 95.6 0.46 0.37–0.58 <0.001 96.9 0.44 0.34–0.58 <0.001
AC-based 1395 90.2 0.76 0.63–0.91 0.003 95.7 0.62 0.48–0.78 <0.001
Others (e.g., CMF) 1479 88.6 1 [Reference] — 92.5 1 [Reference] —
¼ c
axe
Chang et al Medicine  Volume 95, Number 19, May 2016T1-2N1 disease.37,38 In this series, hypermetabolic features in
baseline PET represented a high-risk group having larger
tumors, more positive lymph nodes, a higher LNR, high-grade
tumors, hormone-receptor negativity, or triple-negative status,
and these factors were associated with an increased LRR risk as
well as poor disease-free survival. Several genetic signatures
have been reported to predict risk of distant metastases, expand-
ing the application of genetic analysis for assessing LRR
risk.39–41 Mamounas et al40 retrospectively analyzed >1500
specimens from patients with N0 and estrogen-positive disease
from the NSABP B-14 and B-20 trials, and found that the LRR
risk was significantly associated with recurrence score risk
groups that were quantified using Oncotype DX genetic
analysis. Similar findings were reproduced in patients with
ductal carcinoma in situ.42 Although these new findings regard-
ing PET imaging and gene signatures need to be validated in the
prospective setting or in node-positive patients, their imple-
mentation in clinical practice would prevent both RT under- and
overtreatment with truly personalized treatment protocols.
There are some limitations to the present study. Given its
retrospective observational study design, there were unmea-
sured patient factors related to prognosis, which might have
influenced RT use. The KBCR database does not contain details
of RT dose, fractionation, field, and technique. However, our
previous study reporting RT patterns of care suggested that it is
likely that a large proportion of our patients received RT in a
relatively homogenous manner.43 Other limitations of this study
included the lack of KBCR data on details of performance
status, socioeconomic and demographic characteristics, patient
preferences, physician interaction, and comorbidities. The
impact of HER2 status and trastuzumab could not be analyzed
in this study. As with all national large databases, miscoding of
variables is possible. The KBCR database represents the
majority of breast cancer patients in Korea, while the SEER
database represents only approximately 26% of cancer patients
in the United States.44
In summary, amongwomen diagnosedwith pT1-2N1 breast
cancer in Korea, the percentage undergoing postmastectomy RT
over a 15-year period was relatively low, but gradually increased
during the study period. Although an international consensus
recommends postmastectomy RT for N1 patients if there are
additional adverse features, our study found that several import-
ant well-established risk factors have been de-emphasized
in actual clinical practice in Korea. Our concern is that, with
advances in surgical techniques and modern chemotherapy regi-
AC¼ adriamycin cyclophosphamide, CI¼ confidence interval, CMF
survival, HR¼ hazard ratio, OS¼ overall survival, T¼ paclitaxel docetmens, patients are now expected to have far superior survival
outcomes with a lowLRR risk when compared with those treated
in previous years; therefore, more careful patient selection is
8 | www.md-journal.comneeded. There is a significant unmet need to educate surgeons and
medical and radiation oncologists for better risk stratification of
such patients with the incorporation of tumor biologic factors,
well-established risk factors, and conventional anatomic factors.
As mentioned by Jagsi et al,27 surgeon participation in the RT
decision has a strong impact on RT use, especially among
mastectomy patients. Further effort is needed to investigate
effective predictive markers for RT as well as to optimize the
postmastectomy RT technique, dose, and volume.
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